SCRT2 is a neural-specific zinc-finger transcription factor that functions as a transcriptional repressor of basic helix-loop-helix (bHLH) proteins during brain development 1. In the developing neocortex, SCRT2 is expressed in both mitotic progenitors and postmitotic neurons, where it negatively regulates bHLH transcription factors Ngn2/NeuroD1 on E-box-containing target genes 1. Mechanistically, SCRT2 promotes neuronal differentiation by favoring direct neurogenesis of radial glial progenitors while suppressing intermediate progenitor generation and delaying radial migration of upper layer neurons through repression of Rnd2, a key effector of neuronal migration 1. SCRT2 also mediates neuronal delamination from the apical neuroepithelium through transcriptional repression of E-cadherin, functioning as a molecular link between neuronal fate commitment and migration onset via an epithelial-mesenchymal transition-like mechanism 2. Clinically, SCRT2 has emerged as a biomarker for predicting recurrence risk in IDH-mutant gliomas; elevated SCRT2 expression is associated with increased risk of early recurrence in these lethal brain tumors and improves patient stratification when integrated with imaging and proteomic signatures 3. SCRT2 also exhibits epigenetic sensitivity, with DNA methylation near SCRT2 associated with high prenatal perfluorooctanoic acid exposure 4.